Monoclonal Antibody for pY1235-MET Detection Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing MET activation and signaling, particularly phosphorylation at Y1235, are hindered by the lack of specific binding reagents that do not cross-react with other phosphorylation sites, making it difficult to detect and quantify effectively.
Innovation Solution
Development of a monoclonal antibody specifically binding to pY1235-MET, with defined complementary determining regions (CDRs) in its variable regions, allowing for precise detection and measurement of pY1235-MET in samples, along with methods for producing and using this antibody for immunological assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing binding reagents are used to detect MET phosphorylation, then detection capability is provided, but cross-reactivity with other phosphorylation sites occurs reducing measurement precision
Solution Approach 1:
The patent applies local quality by designing the antibody to recognize a specific local epitope (phosphorylated tyrosine at position 1235) rather than the entire MET protein. The CDRs are engineered to target the precise phosphorylation site, allowing the antibody to distinguish pY1235-MET from other phosphorylated forms of MET or similar proteins, thereby achieving high measurement precision through localized recognition.
2Measurement precision
If existing binding reagents are used, then general detection is possible, but specific detection of pY1235-MET without cross-reactivity cannot be achieved
Solution Approach 1:
The patent applies parameter changes by modifying the binding characteristics of the antibody through specific CDR sequences that are tuned to recognize the phosphorylated tyrosine at position 1235. The antibody was raised against a phosphorylated peptide antigen, which changed the binding parameters to specifically recognize the phosphoepitope, enabling specific detection of pY1235-MET without cross-reactivity to other phosphorylation sites.
3Measurement precision
If non-specific binding reagents are used, then detection of MET can be performed, but accurate quantification of pY1235-MET phosphorylation is hindered
Solution Approach 1:
The patent applies the intermediary principle by using a highly specific antibody as a mediator between the pY1235-MET target and the detection system. The antibody serves as a selective intermediary that binds only to the phosphorylated form at position 1235, allowing accurate quantification and reliable assessment of MET activation without interference from other phosphorylated forms or similar proteins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate detection and quantification of pY1235-MET, facilitating the assessment of MET activation and the evaluation of MET inhibitors, guiding clinical development and treatment decisions.
Implementation Method 1
an antibody that specifically binds to pY1235-MET
Data Source
AI summary
Methods and compositions are described herein for assaying the presence or absence of pY1235-MET or a fragment thereof.